875004-84-5

Upstream product

• 387827-25-0 N-[3-(piperidin-4-yl)phenyl]-acetamide 
• 574-98-1 2-(2-bromoethyl)isoindoline-1,3-dione 
• 527758-03-8 N-(2-bromoethyl)phthalamide 

Downstream Products

• 1431734-23-4 N-{2-[4-(3-acetamidophenyl)piperidin-1-yl]ethyl}-5-(pyridin-4-yl)naphtho[1,2-b]furan-2-carboxamide 
• 1431734-21-2 N-{2-[4-(3-acetamidophenyl)piperidin-1-yl]ethyl}-5-(4-cyanophenyl)naphtho[1,2-b]furan-2-carboxamide 
• 875004-85-6 N-{3-[1-(2-aminoethyl)piperidin-4-yl]phenyl}acetamide 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of naphtho[1,2- B]furan-2-carboxamide derivatives as melanin concentrating hormone receptor 1 antagonists

The discovery that novel naphtho[1,2- b]furan-2-carboxamides containing linked piperidinylphenylacetamide groups serve as melanin concentrating hormone receptor 1 (MCH-R1) antagonists is described. An extensive structure-activity relationship (SAR) study,

MEDICINAL USE OF RECEPTOR LIGANDS

Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1 R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5-membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or -OCH3; X is =CH- or =N-; L, is -CH2- or -CH2CH2- ; L2 is a bond, -CH2- or -CO-; R2 is H or C,-C3 alkyl, or -N(R2) L,- is selected from specific cyclic amino linker radicals as defined in the specification; ring A is selected from specific N- containing heterocyclic rings as defined in the specification.